Associate Professor Nikolas Haass

Honorary Professor
Dermatology, Central Clinical School

Telephone +61 7 3443 7087
Fax +61 7 3443 6966

Curriculum vitae Curriculum vitae

Map

Biographical details

Current positions:

Professor for Cutaneous Oncology, Principal Research Fellow

University of Queensland Diamantina Institute/Translational Research Institute

Department of Dermatology, Princess Alexandra Hospital, School of Medicine, Faculty of Health Sciences

University of Queensland, Brisbane, QLD, Australia

Honorary Professor

Discipline of Dermatology, Central Clinical School

University of Sydney, Sydney, NSW, Australia

Adjunct Associate Faculty, Group Leader ?Experimental Melanoma Therapy?

Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia

2007-2013:

Cameron Melanoma Research Fellow Senior Lecturer, Discipline of Dermatology/Royal Prince Alfred Hospital, The University of Sydney, NSW, Australia

Associate Faculty at the Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, Australia.

2003-2007:

Postdoctoral Fellowship at the Wistar Institute, Philadelphia, PA, USA.

1999-2003:

Resident/registrar at the Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Germany.

1990-1998:

Medical School at the University of Heidelberg, Germany, and Doctoral thesis at the Department of Cell Biology, German Cancer Research Center, Heidelberg, Germany.

Research interests

Prof Nikolas Haass is a clinician scientist specializing in skin cancers. His interests is the understanding of (1) cell-cell and cell-matrix interactions of melanoma with its microenvironment (2) signalling pathways in melanoma, particularly with regards to identifying novel melanoma therapies and (3) the characterization of melanoma cell subpopulations. The techniques he uses include several three-dimensional cell culture models, which recreate the correct interactions of the melanoma with its tumour microenvironment and thus predict the effects of drugs on the tumour in a much better way than the conventional two-dimensional cell culture models. For his mouse models his team applies cutting-edge intravital multi-photon microscopy.

Publications:

For full list please see CV or PubMed:

**http://www.ncbi.nlm.nih.gov/pubmed/?term=haass+nk+or+haass+n**

Research Support:

For full list please see CV.

Current grants:

14. Project Grant “Elucidating the consequences of manipulating the intrinsic apoptosis pathway for melanomagenesis and for melanoma drug resistance in a mouse model” (CIA N. Mohana-Kumaran, CIB N.K. Haass), 01/12/2013 - 30/11/2016 (RM 149,000 for three years)

15. Novogen Research Contract “Evaluation of activity and mechanism of action (MOA) of Novogen's proprietary Anti-tropomyosin (ATM) compounds in molecularly characterised in vitro and in vivo melanoma models” (B. Gabrielli, N.K. Haass), Novogen, 2014-2015 ($ 319,583)

16. NHMRC Project Grant 1084893“Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging” (CIA N.K. Haass, CIB B. Gabrielli, CIC H. Schaider), NHMRC, 1/1/2015-12/31/2017 ($ 594,492 for three years)

Teaching and supervision

Skin cancer

Cancer cell biology

Cancer models and imaging

Current projects

Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging

Effect of three-dimensional tumour organisation on the sensitivity of individual melanoma cells to endoplasmic reticulum stress

The role of Rab27a and Rab5a in melanoma phenotype switching

Evaluation of activity and mechanism of action (MOA) of Novogen's proprietary Anti-tropomyosin (ATM) compounds in molecularly characterised in vitro and in vivo melanoma models

Elucidating the consequences of manipulating the intrinsic apoptosis pathway for melanomagenesis and for melanoma drug resistance in a mouse model

Awards and honours

see CV

International links

Germany

(Johannes Gutenberg-University) nanoparticles

Germany

(University of Hamburg) cell-cell communication

Iran

(National Institute of Genetic Engineering and Biotechnology (NIGEB)) miRNAs in melanoma

United Kingdom

(Manchester Cancer Research Centre) targeted therapy, drug resistance, tumour heterogeneity

United States

(Moffitt Cancer Center) Targeted therapy, drug resistance

United States

(The Wistar Institute) Targeted therapy, drug resistance

United States

(University of Pennsylvania) biomarkers

Selected grants

2013

  • Effect of three-dimensional tumour organisation on the sensitivity of individual melanoma cells to endoplasmic reticulum stress; Haass N, Beaumont K, Weninger W; Cancer Council New South Wales/Research Project Grants.

2011

  • Real-time Imaging of cell cycle progression in melanoma; Haass N, Weninger W; National Health and Medical Research Council (NHMRC)/Project Grants.
  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • High speed 3D live cell imaging of cancer genesis, growth, metastasis and death.; Weninger W, Vadas M, Richardson D, Fazekas de St Groth B, Gamble J, McCaughan G, Rasko J, Shackel N, Haass N; Cancer Institute New South Wales/Equipment Grant.
  • Biological functions of the TAR DNA binding protein 43; Ittner L, Goetz J, Haass N; Australian Research Council (ARC)/Discovery Projects (DP).
  • Next-generation high-speed flow cytometric cell sorter; Fazekas de St Groth B, King N, Simpson S, Britton W, Campbell I, Vadas M, Grau G, Weninger W, Christopherson R, Gamble J, Rasko J, McCaughan G, Xia P, Beale P, Holst J, Haass N, Combes V, Saunders B, Byrne S, West N, Gorrell M, Bertolino P, Bowen D, Warner F, Seth D, Grimshaw M, Jolly C, Martiniello-Wilks R, Mrass P, Lyons G, Sword G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • Multi-photon microscope for intravital imaging; Weninger W, Vadas M, Hogg P, Norris M, Fazekas de St Groth B, Haass N, Clarke S, Halliday G, Rasko J, Holst J, McCaughan G, Allen J, Gamble J, Dong Q, Byrne S, Richardson D; Cancer Institute New South Wales/Equipment Grant.
  • Intravital cell-cycle imaging as a novel approach to design combined targeting strategies of independant signaling pathways in melanoma; Haass N, Ng L; Cancer Institute New South Wales/Research Innovation Grants.
  • The Role of Melanoma Stem Cells in Melanomagnesis; Haass N; Cancer Council New South Wales/Research Project Grants.
  • The Role of Melanoma Stem Cells in Melanomagnesis; Haass N; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Core Resource Facility - application for 7-laser flow cytometer and high content bioimaging system to enhance capabilities and throughput for the NSW Advanced Cytometry Facility; King N, Vadas M, Campbell I, Grau G, Britton W, Fazekas de St Groth B, Richardson D, Halliday G, Christopherson R, Gamble J, Mason R, Rasko J, McCaughan G, Weninger W, Xia P, Gorrell M, Holst J, Pile A, Sword G, McArthur C, Dong Q, Haass N, Sharland A, Saunders B, Triccas J, Norris J, Bertolino P, Bowen D, Sze D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Inverted Multiphoton Intravital Microscope; Weninger W, Gorrell M, Halliday G, Jones C, Fazekas de St Groth B, Richardson D, Clarke S, Gamble J, Bertolino P, Vadas M, Dong Q, Rasko J, Holst J, McCaughan G, Byrne S, Saunders B, Triccas J, Haass N; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2007

  • Cameron Melanoma Research Fellow; Haass N; Melanoma and Skin Cancer Research Institute/Research Grant.

Selected publications & creative works

Download citations: PDF RTF Endnote

Book Chapters

  • Spoerri, L., Oo, Z., Larsen, J., Haass, N., Gabrielli, B., Pavey, S. (2015). Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities. In Georg T. Wondrak (Eds.), Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics, (pp. 29-49). Dordrecht: Springer Science+Business Media.
  • Tonnessen, C., Haass, N. (2015). Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. In Thomas Bieber, Frank Nestle (Eds.), Personalized Treatment Options in Dermatology, (pp. 7-27). Berlin: Springer-Verlag.
  • Kuphal, S., Haass, N. (2011). Cell-Cell and Cell-Matrix Contacts in Melanoma and the Tumor Microenvironment. In Anja Bosserhoff (Eds.), Melanoma Development: Molecular Biology, Genetics and Clinical Application, (pp. 181-215). Vienna: Springer.
  • Haass, N., Hoeller, C., Herlyn, M. (2008). Targeting Signaling Pathways - in the search of Melanoma's Achilles' heel. In Menashe Bar-Eli (Eds.), Regulation of Gene Expression in the Tumor Environment, (pp. 27-42). United States: Springer.

Journals

  • Ravindran Menon, D., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Bonyadi Rad, E., et al (2015). A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene, 34(34), 4448-4459. [More Information]
  • Haass, N. (2015). Dynamic tumor heterogeneity in melanoma therapy: how do we address this in a novel model system? Melanoma Management, 2(2), 93-95.
  • Burke, M., Morais, C., Oliver, K., Lambie, D., Gobe, G., Carroll, R., Staatz, C., Sinnya, S., Soyer, P., Winterford, C., et al (2015). Expression of Bcl-xL and Mcl-1 in the Nonmelanoma Skin Cancers of Renal Transplant Recipients. American Journal of Clinical Pathology, 143(4), 514-526. [More Information]
  • Tikoo, S., Haass, N. (2015). Friends or foes: IL-10 and TGF-β in melanoma. Experimental Dermatology, 24(4), 254-255. [More Information]
  • Beaumont, K., Anfosso, A., Ahmed, F., Weninger, W., Haass, N. (2015). Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids. Journal of Visualized Experiments, 28(106), 1-9. [More Information]
  • Ke, Y., Hummel, A., Stevens, C., Gladbach, A., Ippati, S., Bi, M., Lee, W., Kruger, S., Hoven, J., Volkerling, A., Haass, N., Kiernan, M., et al (2015). Short‑term suppression of A315T mutant human TDP‑43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD‑TDP and ALS. Acta Neuropathologica, 130(5), 661-678. [More Information]
  • Haass, N., Nassif, N., McGowan, E. (2015). Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. BioMed Research International, 2015, 1-9. [More Information]
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • Hill, D., Lovat, P., Haass, N. (2014). Induction of endoplasmic reticulum stress as a strategy for melanoma therapy:is there a future? Melanoma Management, 1(2), 127-137. [More Information]
  • Haass, N., Schumacher, U. (2014). Melanoma never says die. Experimental Dermatology, 23(7), 471-472. [More Information]
  • Beaumont, K., Kumaran - Mohana, N., Haass, N. (2014). Modeling Melanoma In Vitro and In Vivo. Healthcare, 2, 27-46. [More Information]
  • Haass, N., Beaumont, K., Hill, D., Anfosso, A., Mrass, P., Munoz, M., Kinjyo, I., Weninger, W. (2014). Real-time cell cycle imaging during melanoma growth, invasion and drug response. Pigment Cell & Melanoma Research, 27(5), 764-776. [More Information]
  • Wang, K., Beaumont, K., Otte, N., Font Sadurni, J., Bailey, C., van Geldermalsen, M., Sharp, D., Tiffen, J., Ryan, R., Jormakka, M., Haass, N., Rasko, J., Holst, J. (2014). Targeting glutamine transport to suppress melanoma cell growth. International Journal of Cancer, 135(5), 1060-1071. [More Information]
  • Mohana-Kumaran, N., Hill, D., Allen, D., Haass, N. (2014). Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell & Melanoma Research, 27(4), 525-539. [More Information]
  • Stehn, J., Haass, N., Bonello, T., Desouza, M., Kottyan, G., Treutlein, H., Zeng, J., Nascimento, P., Sequeira, V., Butler, T., Allanson, M., Winlaw, D., Reeve, V., Weninger, W., et al (2013). A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. Cancer Research, 73(16), 5169-5182. [More Information]
  • Tong, P., Qin, J., Cooper, C., Lowe, P., Murrell, D., Kossard, S., Ng, L., Roediger, B., Weninger, W., Haass, N. (2013). A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. British Journal of Dermatology, 169(4), 869-879. [More Information]
  • Pavey, S., Spoerri, L., Haass, N., Gabrielli, B. (2013). DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell & Melanoma Research, 26(6), 805-816. [More Information]
  • Brandner, J., Haass, N. (2013). Melanoma's connections to the tumour microenvironment. Pathology, 45(5), 443-452. [More Information]
  • Wroblewski, D., Mijatov, B., Mohana-Kumara, N., Lai, F., Gallagher, S., Haass, N., Zhang, X., Hersey, P. (2013). The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 34(2), 237-247. [More Information]
  • Smalley, K., Aplin, A., Flaherty, K., Hoeller, C., Bosserhoff, A., Haass, N., Bosenberg, M., Ribas, A., Barnhill, R., Kudchadkar, R., et al (2012). Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell & Melanoma Research, 25(1), E1-E11. [More Information]
  • Lucas, K., Kumaran - Mohana, N., Lau, D., Zhang, X., Hersey, P., Huang, D., Weninger, W., Haass, N., Allen, J. (2012). Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 18(3), 783-795. [More Information]
  • McGowan, E., Alling, N., Jackson, E., Yagoub, D., Haass, N., Allen, J., Martinello-Wilks, R. (2011). Evaluation of Cell Cycle Arrest in Estrogen Responsive MCF-7 Breast Cancer Cells: Pitfalls of the MTS Assay. PloS One, 6(6), 1-8. [More Information]
  • Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]
  • de Zwaan, S., Haass, N. (2010). Genetics of basal cell carcinoma. Australasian Journal of Dermatology, 51(2), 81-92; quiz 93-4. [More Information]
  • Haass, N., Ripperger, D., Wladykowski, E., Dawson, P., Gimotty, P., Blome, C., Fischer, F., Schmage, P., Moll, I., Brandner, J. (2010). Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment. Histochemistry and Cell Biology, 133(1), 113-124. [More Information]
  • Cocciolone, R., Crotty, K., Andrews, L., Haass, N., Moloney, F. (2010). Multiple Desmoplastic Melanomas in Birt-Hogg-Dube Syndrome and a Proposed Signaling Link Between Folliculin, the mTOR Pathway, and Melanoma Susceptibility. Archives of Dermatology, 146(11), 1316-1318. [More Information]
  • Lee, J., Li, L., Brafford, P., van den Eijnden, M., Halloran, M., Sproesser, K., Haass, N., Smalley, K., Tsai, J., Bollag, G., et al (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research, 23(6), 820-827. [More Information]
  • Santiago-Walker, A., Li, L., Haass, N., Herlyn, M. (2009). Melanocytes: from morphology to application. Skin Pharmacology and Physiology, 22(2), 114-121. [More Information]
  • Haass, N., Smalley, K. (2009). Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Molecular Diagnosis and Therapy, 13(5), 283-296. [More Information]
  • Tsai, J., Lee, J., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N., et al (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(8), 3041-3046. [More Information]
  • Haass, N. (2008). From xiphophorus to melanoma-a tribute to steven kazianis (1966-2008). Zebrafish, 5(2), 91-92. [More Information]
  • Smalley, K., Lioni, M., Noma, K., Haass, N., Herlyn, M. (2008). In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion on Drug Discovery, 3(1), 1-10. [More Information]
  • Haass, N., Sproesser, K., Nguyen, T., Contractor, R., Medina, C., Nathanson, K., Herlyn, M., Smalley, K. (2008). The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clinical Cancer Research, 14(1), 230-239. [More Information]
  • Smalley, K., Contractor, R., Haass, N., Kulp, A., Atilla-Gokcumen, G., Williams, D., Bregman, H., Flaherty, K., Soengas, M., Meggers, E., et al (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Research, 67(1), 209-217. [More Information]
  • Wenke, A., Kjellman, C., Lundgren-Akerlund, E., Uhlmann, C., Haass, N., Herlyn, M., Bosserhoff, A. (2007). Expression of integrin alpha10 is induced in malignant melanoma. Cellular Oncology, 29(5), 373-386. [More Information]
  • Smalley, K., Contractor, R., Haass, N., Lee, J., Nathanson, K., Medina, C., Flaherty, K., Herlyn, M. (2007). Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. British Journal of Cancer, 96(3), 445-449. [More Information]
  • Haass, N., Wladykowski, E., Kief, S., Moll, I., Brandner, J. (2006). Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 54(2), 171-182. [More Information]
  • Smalley, K., Haass, N., Brafford, P., Lioni, M., Flaherty, K., Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics, 5(5), 1136-1144. [More Information]
  • Haass, N., Smalley, K., Li, L., Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Research, 18(3), 150-159. [More Information]
  • Haass, N., Herlyn, M. (2005). Normal human melanocyte homeostasis as a paradigm for understanding melanoma. The journal of investigative dermatology. Symposium proceedings, 10(2), 153-163. [More Information]
  • Smalley, K., Brafford, P., Haass, N., Brandner, J., Brown, E., Herlyn, M. (2005). Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. The American Journal of Pathology, 166(5), 1541-1554. [More Information]

Conferences

  • Coates, E., Moloney, F., Guitera, P., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Melanoma detection in high risk patients: a case series. 20th Regional Conference of Dermatology 2012.
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Observation of a five year high risk clinic for primary melanoma. 3rd World Congress of Dermoscopy, Australia.

Research Reports

  • Haass, N. (2014). The Petrel 2014: Annual Report for Southport The Brisbane Seabird Study Group SOSSA, Northern Sector | The Grey-headed Albatross conundrum at the Australian east coast, (pp. 96 - 107). Brisbane, QLD, Australia: SOSSA.

2015

  • Ravindran Menon, D., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Bonyadi Rad, E., et al (2015). A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene, 34(34), 4448-4459. [More Information]
  • Spoerri, L., Oo, Z., Larsen, J., Haass, N., Gabrielli, B., Pavey, S. (2015). Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities. In Georg T. Wondrak (Eds.), Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics, (pp. 29-49). Dordrecht: Springer Science+Business Media.
  • Haass, N. (2015). Dynamic tumor heterogeneity in melanoma therapy: how do we address this in a novel model system? Melanoma Management, 2(2), 93-95.
  • Burke, M., Morais, C., Oliver, K., Lambie, D., Gobe, G., Carroll, R., Staatz, C., Sinnya, S., Soyer, P., Winterford, C., et al (2015). Expression of Bcl-xL and Mcl-1 in the Nonmelanoma Skin Cancers of Renal Transplant Recipients. American Journal of Clinical Pathology, 143(4), 514-526. [More Information]
  • Tikoo, S., Haass, N. (2015). Friends or foes: IL-10 and TGF-β in melanoma. Experimental Dermatology, 24(4), 254-255. [More Information]
  • Beaumont, K., Anfosso, A., Ahmed, F., Weninger, W., Haass, N. (2015). Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids. Journal of Visualized Experiments, 28(106), 1-9. [More Information]
  • Tonnessen, C., Haass, N. (2015). Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. In Thomas Bieber, Frank Nestle (Eds.), Personalized Treatment Options in Dermatology, (pp. 7-27). Berlin: Springer-Verlag.
  • Ke, Y., Hummel, A., Stevens, C., Gladbach, A., Ippati, S., Bi, M., Lee, W., Kruger, S., Hoven, J., Volkerling, A., Haass, N., Kiernan, M., et al (2015). Short‑term suppression of A315T mutant human TDP‑43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD‑TDP and ALS. Acta Neuropathologica, 130(5), 661-678. [More Information]
  • Haass, N., Nassif, N., McGowan, E. (2015). Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. BioMed Research International, 2015, 1-9. [More Information]

2014

  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • Hill, D., Lovat, P., Haass, N. (2014). Induction of endoplasmic reticulum stress as a strategy for melanoma therapy:is there a future? Melanoma Management, 1(2), 127-137. [More Information]
  • Haass, N., Schumacher, U. (2014). Melanoma never says die. Experimental Dermatology, 23(7), 471-472. [More Information]
  • Beaumont, K., Kumaran - Mohana, N., Haass, N. (2014). Modeling Melanoma In Vitro and In Vivo. Healthcare, 2, 27-46. [More Information]
  • Haass, N., Beaumont, K., Hill, D., Anfosso, A., Mrass, P., Munoz, M., Kinjyo, I., Weninger, W. (2014). Real-time cell cycle imaging during melanoma growth, invasion and drug response. Pigment Cell & Melanoma Research, 27(5), 764-776. [More Information]
  • Wang, K., Beaumont, K., Otte, N., Font Sadurni, J., Bailey, C., van Geldermalsen, M., Sharp, D., Tiffen, J., Ryan, R., Jormakka, M., Haass, N., Rasko, J., Holst, J. (2014). Targeting glutamine transport to suppress melanoma cell growth. International Journal of Cancer, 135(5), 1060-1071. [More Information]
  • Mohana-Kumaran, N., Hill, D., Allen, D., Haass, N. (2014). Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell & Melanoma Research, 27(4), 525-539. [More Information]
  • Haass, N. (2014). The Petrel 2014: Annual Report for Southport The Brisbane Seabird Study Group SOSSA, Northern Sector | The Grey-headed Albatross conundrum at the Australian east coast, (pp. 96 - 107). Brisbane, QLD, Australia: SOSSA.

2013

  • Stehn, J., Haass, N., Bonello, T., Desouza, M., Kottyan, G., Treutlein, H., Zeng, J., Nascimento, P., Sequeira, V., Butler, T., Allanson, M., Winlaw, D., Reeve, V., Weninger, W., et al (2013). A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. Cancer Research, 73(16), 5169-5182. [More Information]
  • Tong, P., Qin, J., Cooper, C., Lowe, P., Murrell, D., Kossard, S., Ng, L., Roediger, B., Weninger, W., Haass, N. (2013). A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. British Journal of Dermatology, 169(4), 869-879. [More Information]
  • Pavey, S., Spoerri, L., Haass, N., Gabrielli, B. (2013). DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell & Melanoma Research, 26(6), 805-816. [More Information]
  • Brandner, J., Haass, N. (2013). Melanoma's connections to the tumour microenvironment. Pathology, 45(5), 443-452. [More Information]
  • Wroblewski, D., Mijatov, B., Mohana-Kumara, N., Lai, F., Gallagher, S., Haass, N., Zhang, X., Hersey, P. (2013). The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 34(2), 237-247. [More Information]

2012

  • Smalley, K., Aplin, A., Flaherty, K., Hoeller, C., Bosserhoff, A., Haass, N., Bosenberg, M., Ribas, A., Barnhill, R., Kudchadkar, R., et al (2012). Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell & Melanoma Research, 25(1), E1-E11. [More Information]
  • Coates, E., Moloney, F., Guitera, P., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Melanoma detection in high risk patients: a case series. 20th Regional Conference of Dermatology 2012.
  • Lucas, K., Kumaran - Mohana, N., Lau, D., Zhang, X., Hersey, P., Huang, D., Weninger, W., Haass, N., Allen, J. (2012). Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 18(3), 783-795. [More Information]
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Observation of a five year high risk clinic for primary melanoma. 3rd World Congress of Dermoscopy, Australia.

2011

  • Kuphal, S., Haass, N. (2011). Cell-Cell and Cell-Matrix Contacts in Melanoma and the Tumor Microenvironment. In Anja Bosserhoff (Eds.), Melanoma Development: Molecular Biology, Genetics and Clinical Application, (pp. 181-215). Vienna: Springer.
  • McGowan, E., Alling, N., Jackson, E., Yagoub, D., Haass, N., Allen, J., Martinello-Wilks, R. (2011). Evaluation of Cell Cycle Arrest in Estrogen Responsive MCF-7 Breast Cancer Cells: Pitfalls of the MTS Assay. PloS One, 6(6), 1-8. [More Information]
  • Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]

2010

  • de Zwaan, S., Haass, N. (2010). Genetics of basal cell carcinoma. Australasian Journal of Dermatology, 51(2), 81-92; quiz 93-4. [More Information]
  • Haass, N., Ripperger, D., Wladykowski, E., Dawson, P., Gimotty, P., Blome, C., Fischer, F., Schmage, P., Moll, I., Brandner, J. (2010). Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment. Histochemistry and Cell Biology, 133(1), 113-124. [More Information]
  • Cocciolone, R., Crotty, K., Andrews, L., Haass, N., Moloney, F. (2010). Multiple Desmoplastic Melanomas in Birt-Hogg-Dube Syndrome and a Proposed Signaling Link Between Folliculin, the mTOR Pathway, and Melanoma Susceptibility. Archives of Dermatology, 146(11), 1316-1318. [More Information]
  • Lee, J., Li, L., Brafford, P., van den Eijnden, M., Halloran, M., Sproesser, K., Haass, N., Smalley, K., Tsai, J., Bollag, G., et al (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research, 23(6), 820-827. [More Information]

2009

  • Santiago-Walker, A., Li, L., Haass, N., Herlyn, M. (2009). Melanocytes: from morphology to application. Skin Pharmacology and Physiology, 22(2), 114-121. [More Information]
  • Haass, N., Smalley, K. (2009). Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Molecular Diagnosis and Therapy, 13(5), 283-296. [More Information]

2008

  • Tsai, J., Lee, J., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N., et al (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(8), 3041-3046. [More Information]
  • Haass, N. (2008). From xiphophorus to melanoma-a tribute to steven kazianis (1966-2008). Zebrafish, 5(2), 91-92. [More Information]
  • Smalley, K., Lioni, M., Noma, K., Haass, N., Herlyn, M. (2008). In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion on Drug Discovery, 3(1), 1-10. [More Information]
  • Haass, N., Hoeller, C., Herlyn, M. (2008). Targeting Signaling Pathways - in the search of Melanoma's Achilles' heel. In Menashe Bar-Eli (Eds.), Regulation of Gene Expression in the Tumor Environment, (pp. 27-42). United States: Springer.
  • Haass, N., Sproesser, K., Nguyen, T., Contractor, R., Medina, C., Nathanson, K., Herlyn, M., Smalley, K. (2008). The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clinical Cancer Research, 14(1), 230-239. [More Information]

2007

  • Smalley, K., Contractor, R., Haass, N., Kulp, A., Atilla-Gokcumen, G., Williams, D., Bregman, H., Flaherty, K., Soengas, M., Meggers, E., et al (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Research, 67(1), 209-217. [More Information]
  • Wenke, A., Kjellman, C., Lundgren-Akerlund, E., Uhlmann, C., Haass, N., Herlyn, M., Bosserhoff, A. (2007). Expression of integrin alpha10 is induced in malignant melanoma. Cellular Oncology, 29(5), 373-386. [More Information]
  • Smalley, K., Contractor, R., Haass, N., Lee, J., Nathanson, K., Medina, C., Flaherty, K., Herlyn, M. (2007). Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. British Journal of Cancer, 96(3), 445-449. [More Information]

2006

  • Haass, N., Wladykowski, E., Kief, S., Moll, I., Brandner, J. (2006). Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 54(2), 171-182. [More Information]
  • Smalley, K., Haass, N., Brafford, P., Lioni, M., Flaherty, K., Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics, 5(5), 1136-1144. [More Information]

2005

  • Haass, N., Smalley, K., Li, L., Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Research, 18(3), 150-159. [More Information]
  • Haass, N., Herlyn, M. (2005). Normal human melanocyte homeostasis as a paradigm for understanding melanoma. The journal of investigative dermatology. Symposium proceedings, 10(2), 153-163. [More Information]
  • Smalley, K., Brafford, P., Haass, N., Brandner, J., Brown, E., Herlyn, M. (2005). Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. The American Journal of Pathology, 166(5), 1541-1554. [More Information]

To update your profile click here. For support on your academic profile contact .